^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + Empliciti (elotuzumab) (CS-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Published date:
09/04/2020
Excerpt:
In addition, ERd was associated with an OS benefit in other clinically relevant subgroups of interest, including patients with high-risk disease (median, 29.8 vs 24.8 months; HR, 0.69; 95% CI, 0.46–1.03), del(17p) mutations in ≥1 cell...
Secondary therapy:
dexamethasone
DOI:
10.1038/s41408-020-00357-4
Trial ID:
Source:
Title:
Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.
Published date:
05/26/2022
Excerpt:
High risk cytogenetics were defined as del17p, t(4;14), t(14;16), 1q21 gain or amplification by fluorescence in situ hybridization....Len-combo regimens were either doublets (Len with dexamethasone [dex: n = 10], elotuzumab [n = 28] or ixazomib [n = 14]) or triplets (Len with bortezomib/dex [n = 10], ixazomib/dex [n = 10] or carfilzomib/dex [n = 6])...for patients with HR cytogenetic abnormalities other than 1q+ there was a trend towards better PFS with Len-combo (HR 0.59, CI 0.32-1.09, p = 0.09), without a difference in OS (HR: 0.79, CI: 0.37-1.65, p = 0.53)….In this single center retrospective analysis, intensification of post-transplant Len maintenance did not show an improvement in outcomes for HRMM patients. However, there was a trend towards improved PFS in patients with HR abnormalities other than 1q+.
DOI:
10.1200/JCO.2022.40.16_suppl.e20024
